From Zacks Investment Research.: 2025-06-02 08:20:00

Amplify Weight Loss Drug & Treatment ETF (THNR) has hit a 52-week high, up 51.9% from its low of $18.56/share. The underlying VettaFi Weight Loss Drug & Treatment Index includes global companies in the GLP-1 agonist pharmaceutical business, charging 59 bps in annual fees. The ETF has large holdings in Novo Nordisk and Eli Lilly, both gaining over 2% on May 30, 2025. Despite this, THNR might struggle in the near term with a negative weighted alpha of 12.86. Investors are watching closely to see if more gains are in store for this momentum-driven ETF.



Read more at Zacks Investment Research.: Weight Loss Drug ETF (THNR) Hits New 52-Week High – June 2, 2025